Tae-Wook Chun, Ph.D.

Stadtman Investigator

HIV Immunovirology Unit

NIAID/DIR

10 Center Drive
Building 10
Room 6A33
Bethesda, MD 20892

301-496-0890

twchun@niaid.nih.gov

Research Topics

Our research program focuses on 1) delineating the role of viral reservoirs in the pathogenesis of HIV disease; 2) examining host and viral factors that contribute to the maintenance of HIV reservoirs; and 3) developing therapeutic strategies aimed at achieving durable virologic control in infected individuals in the absence of antiretroviral therapy. Our research program utilizes Bench-to-Bedside approaches. We conduct comprehensive genetic, immunologic, and virologic analyses of CD4+ and CD8+ T cells in diverse cohorts of HIV-infected individuals in order to address fundamental pathogenic questions, such as elucidating mechanisms of viral persistence, the role of the host immunity in containment of viral replication, and evaluating promising novel therapeutic agents in both ex vivo and in vivo settings. Based on findings from bench research, we also conduct phase I clinical trials in close collaboration with the NIAID HIV clinic, with the ultimate goal of developing safe, effective, and scalable therapeutic strategies that would allow HIV-infected individuals to control viral replication in the absence of daily antiretroviral drugs.

Biography

Dr. Chun received his Ph.D. from the Biochemistry, Cellular, and Molecular Biology Graduate Program from the Johns Hopkins University School of Medicine where he discovered and characterized latently infected, resting CD4+ T cells in HIV-infected individuals. He began his postdoctoral work in the Laboratory of Immunoregulation at NIAID as a research fellow in 1997. Subsequently, Dr. Chun was appointed to the position of staff scientist in 2001. Dr. Chun was selected as one of the Earl Stadtman Investigators and received a tenure track investigator position in the LIR in June 2016.

Selected Publications

  1. Huiting ED, Gittens K, Justement JS, Shi V, Blazkova J, Benko E, Kovacs C, Wender PA, Moir S, Sneller MC, Fauci AS, Chun TW. Impact of Treatment Interruption on HIV Reservoirs and Lymphocyte Subsets in Individuals Who Initiated Antiretroviral Therapy During the Early Phase of Infection. J Infect Dis. 2019;220(2):270-274.

  2. Wang CY, Wong WW, Tsai HC, Chen YH, Kuo BS, Lynn S, Blazkova J, Clarridge KE, Su HW, Lin CY, Tseng FC, Lai A, Yang FH, Lin CH, Tseng W, Lin HY, Finstad CL, Wong-Staal F, Hanson CV, Chun TW, Liao MJ. Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption. N Engl J Med. 2019;380(16):1535-1545.

  3. Clarridge KE, Blazkova J, Einkauf K, Petrone M, Refsland EW, Justement JS, Shi V, Huiting ED, Seamon CA, Lee GQ, Yu XG, Moir S, Sneller MC, Lichterfeld M, Chun TW. Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals. PLoS Pathog. 2018;14(1):e1006792.

  4. Sneller MC, Justement JS, Gittens KR, Petrone ME, Clarridge KE, Proschan MA, Kwan R, Shi V, Blazkova J, Refsland EW, Morris DE, Cohen KW, McElrath MJ, Xu R, Egan MA, Eldridge JH, Benko E, Kovacs C, Moir S, Chun TW, Fauci AS. A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection. Sci Transl Med. 2017;9(419).

  5. Nishimura Y, Gautam R, Chun TW, Sadjadpour R, Foulds KE, Shingai M, Klein F, Gazumyan A, Golijanin J, Donaldson M, Donau OK, Plishka RJ, Buckler-White A, Seaman MS, Lifson JD, Koup RA, Fauci AS, Nussenzweig MC, Martin MA. Early antibody therapy can induce long-lasting immunity to SHIV. Nature. 2017;543(7646):559-563.


This page was last updated on August 17th, 2019